SUPPLEMENTARY MATERIALS.

Treatment recommendations based on Network Meta-Analysis: rules for risk-averse decision-makers

Authors: A E Ades¹, Hugo Pedder¹, Annabel L Davies¹, H Thom¹, David M Phillippo¹, Beatrice Downing¹, Deborah M Caldwell¹, Nicky J Welton¹.

A. Detailed results on NMAs from NICE guidelines

A1: Moderate to Severe Acne

A2: Mild to Moderate Acne

A3: More Severe Depression

A4: Tranexamic Acid in Joint Replacement

A5: Headache prophylaxis

A6: Social Anxiety (Treatment)

A7: Social Anxiety (Class)

A8: Urinary Incontinence

A9: Tocolytic Therapy

- B. WinBUGS code for illustrative examples
- C. WinBUGS code for NICE Guidelines
- D. References

Note on the Supplementary Tables and Figures.

The tables show the results of applying the decision rules and ranking systems in a series of NMAs from Nice guidelines. All the rankings refer to the ranks generated by the EV. For the EV, LaEV, and GRADE decision rules, the shaded rankings indicate which treatments pass the Stage 1 criteria and are recommended at Stag3 2. Note that, at Stage 2, the treatments that are top-ranked by EV and LaEV are the reference treatments, and the value of the Stage 2 evaluative function is the MCID with no uncertainty.

For the probabilistic rankings, we have shaded the N top-ranked treatments, where N is the number of treatments recommended by EV

The figures are caterpillar plots of the EV (blue dots) and its 95%CrI, and LaEV(red circles) of the Stage 1 and Stage 2 evaluation functions, ordered by EV. Also shown: the coding of treatments in NICE guidelines; the MCID at Stage 2 (dotted line). Treatments recommended are those with EV, or LaEV, to the right of the zero (dashed) line in Stage 2. GRADE recommended treatments are those in bold and marked with asterisks.

LaEV SUPP June 18 2024

¹ Population Health Sciences, Bristol University Medical School, Bristol, United Kingdom

APPENDIX A: DETAILED RESULTS ON NMAS FROM NICE GUIDEINES

A1. Moderate-to-Severe Acne¹

Table S1

Tuble 31					STAG	iE 1 Rules									STAGE 2		
Treatment (numbering as in NICE guidel	ines)		EV	Dec		aEV	(GRADE 0.975) tegory 1	Rank	ing sys	tems		EV	Dec	cision Ru La	aEV	GRADE (0.975) Category
		Rk	EV	Sd	Rk	LaEV	Rk	Pr(V>T)	P(Best)	SUCRA	Pr(V>T)	Rk	EV	sd	Rk	LaEV	1
Retinoid tcd ≥ 120mg/kg (sc)[o]	9	1	58.0	10.7	1	58.0	1	0.999	2	1	1	1(R)	25.0	0 (R)	1(R)	25.0	1
*PhTh therapy	17	2	57.6	17.4	2	57.6	8	0.994	1	2	8	2	24.6	20.0	2	23.5	8
*Nicotinamide[t]	7	3	49.9	13.8	3	49.9	7	0.993	3	3	7	3	16.9	16.9	3	15.5	7
*PhTh+photodynamic therapy	16	4	47.9	15.4	4	47.9	9	0.984	4	5	9	4	14.9	18.3	4	12.7	9
Retinoid tcd<120mg/kg (sc)[o]	8	5	47.6	14.1	5	47.6	6	0.981	5	4	6	5	14.6	17.2	5	12.7	6
*Tetracycline [oral]+PhDy therapy	27	6	44.8	9.5	6	44.8	2	0.968	6	7	2	6	11.8	13.2	6	10.5	
Lincosamide[t]+Retinoid[t]	22	7	44.5	7.8	7	44.5	3	0.965	11	6	3	7	11.5	12.6	7	10.3	
BP[t]+Retinoid[t]+Tetracycline[o]	26	8	43.5	7.2	8	43.5	12	0.958	7	8	12	8	10.5	8.2	8	10.1	
Photodynamic therapy	15	9	40.5	7.1	9	40.5	5	0.945	18	9	5	9	7.5	12.1	9	5.5	
*No treatment	2	10	39.4	18.7	10	39.2	4	0.931	14	10	4	10	6.4	21.2	10	0.7	
Azelaic acid[t]+Tetracycline[o]	24	11	38.4	15.8	11	38.4	13	0.919	10	11	13	11	5.4	18.7	11	0.4	
Retinoid[t]+Tetracycline[o]	25	12	35.2	5.9	12	35.2	11	0.802	15	12	11	12	2.2	11.1	12	-1.1	
Lincosamide[t]	4	13	34.1	6.6	13	34.1	14	0.791	26	14	14	13	1.1	11.8	13	-3.0	
BP[t]+Retinoid[t]	21	14	34.0	11.1	14	34.0	10	0.782	23	13	10	14	0.9	15.5	14	-4.7	
PhCh therapy[red]	12	15	29.7	11.5	15	29.7	16	0.675	8	15	16	15	-3.3	15.2	15	-11.1	
Benzoyl peroxide[t]	3	16	28.9	8.6	16	28.9	15	0.662	9	16	15	16	-4.1	13.8	16	-11.9	
PhCh+PhTh therapy	14	17	28.3	15.7	17	28.0	17	0.587	16	17	17	17	-4.7	18.6	17	-14.7	
*Co-cyprindiol[o]	11	18	25.0	15.5	18	24.7	18	0.501	21	18	18	18	-8.0	18.9	19	-18.6	
Tetracycline[o]	10	19	24.2	4.1	19	24.2	19	0.423	12	19	19	19	-8.8	10.0	18	-20.1	
BP[t]+Lincosamide[t]+Retinoid[t]	23	20	23.1	7.5	20	23.1	23	0.406	20	20	23	20	-9.9	13.1	20	-21.6	
BP[t]+Lincosamide[t]	19	21	22.7	8.4	21	22.7	20	0.394	17	23	20	21	-10.3	13.6	21	-22.3	
BP[t]+Macrolide[t]	20	22	22.1	4.8	22	22.1	21	0.391	13	21	21	22	-10.9	11.8	22	-22.9	
*BP[t]+Anti-fungal[t]	18	23	22.1	12.2	23	21.9	22	0.272	24	22	22	23	-10.9	16.3	23	-24.2	
Retinoid[t]	5	24	13.1	2.5	24	13.1	26	0.258	25	26	26	24	-19.9	11.0	24	-39.9	
Macrolide[t]	6	25	10.9	7.3	25	10.7	25	0.028	19	24	25	25	-22.1	13.1	25	-44.5	
*PhCh therapy[blue and red]	13	26	8.8	24.8	26	2.8	24	0.000	22	25	24	26	-24.2	26.7	26	-50.7	

Abbreviations: BP Benzoyl peroxide; tcd total cumulative dose; [t] topical; [o] oral; [ph] physical; (sc) single course; ToAc Topical Acid; PhCh Photochemical therapy; PhTh Photothermal therapy; PhDy Photodynamic therapy; Comb. Combined; Rk rank (values are ranks on EV)

Moderate-to-Severe Acne

Type of model: Random study effects, fixed class effects model with 52 treatments in 26 classes relative to placebo.

Outcome: % Change from Baseline.

MCID: 25%, GRADE probability cutoff: 0.975

Decision rules Stage 1:

EV: all 26 treatment classes have positive EV LaEV: all 26 treatment classes have positive LaEV

GRADE: 5 treatments qualify and are promoted to Category 1.

Ranking Systems: Pr(V>T) places treatments ranked 8,7,9,6 on EV among the top 5: these have exceptionally low SD. But both Pr(V>T) and SUCRA pick out the same top 14 treatments as EV. The Pr(Best) ranking is erratic, privileging more uncertain treatments

Decision rules Stage 2:


EV: 13 treatments besides the best treatment are recommended, because they are not worse than the best treatment by more than the MCID.

LaEV: 10 treatments, besides the best treatment would be recommended.

GRADE: none of the 5 Category 1 treatments are significantly better than any other by the MCID. Therefore, none are promoted to Category 2, and all are recommended.

Comments: During consideration of the NMA results by NICE Guidelines developers, a number of treatments were ruled out on the basis of potential bias reflected in their small sample size. These are marked with an asterisk in Table S1. Note that none of those with small sample size would have been ruled out by LaEV.

Figure S1. Moderate to Severe Acne.



A2. Mild to Moderate Acne

Table S2

					STAC										STAGE 2		
Treatmen	•			Dec	cisior	Rules		D 4 D 5	Rank	ing sys	tems			Dec	ision Ru	ues	
(numbering as in NICI	-		EV			aEV	_	RADE 0.975)	IXam	iiig 3y3	tems		EV		La	eΕV	GRADE
(nambering as in wei	L galaciiiles/				-	aL V	,	tegory 1								<i>_</i>	(0.975) Category
		Rk	EV	Sd	Rk	LaEV	Rk	Pr(V>T)	P(Best)	SUCRA	Pr(V>T)	Rk	EV	sd	Rk	LaEV	1
*PhCh [red]	23	1	80.8	40.7	1	80.4	2	0.984	1	2	2	1(R)	25.0	0 (R)	1(R)	25.0	2
*ACNICARE[ph]	15	2	79.2	26.2	2	79.2	3	0.937	2	3	3	2	23.4	48.1	2	13.8	
*PhTh+photodynamic	26	3	64.7	25.9	3	64.7	4	0.933	3	1	4	3	9.0	40.1	3	-2.9	
*Smoothbeam+PhCh [blue]	27	4	51.8	17.7	4	51.8	1	0.921	4	4	1	4	-4.0	43.9	4	-23.6	
Chemical peel[ph]	13	5	36.9	14.0	5	36.9	5	0.803	5	5	5	5	-18.9	42.7	5	-47.0	
PhCh[b&r]	21	6	32.6	9.3	6	32.6	6	0.788	8	6	6	6	-23.2	41.4	6	-53.9	
*Photodynamic	25	7	30.9	21.8	7	30.1	9	0.664	11	9	9	7	-24.9	37.2	8	-55.0	
*No treatment	2	8	29.5	33.1	9	29.5	10	0.660	10	10	10	8	-26.3	27.5	7	-55.4	
*BP[t]+Lincosamide[t]+ToAc[t]	40	9	29.5	10.6	10	29.3	7	0.613	9	12	7	9	-26.3	41.8	9	-59.3	
*Retinoid[t]+H ₂ O ₂ [t]	34	10	29.3	10.5	11	28.4	11	0.593	13	11	11	10	-26.5	41.8	10	-59.7	
*Superoxidised solution[t]	10	11	28.5	14.0	12	27.4	12	0.591	12	14	12	11	-27.3	42.6	11	-61.3	
*Lincosamide[t]+Azelaic acid[t]	31	12	27.5	10.2	13	26.4	8	0.572	6	7	8	12	-28.3	41.6	12	-62.8	
*BP[t]+PhCh+PhTh	41	13	26.5	11.8	8	26.0	13	0.547	40	13	13	13	-29.3	42.1	13	-64.7	
PhCh [blue]	22	14	25.9	8.5	14	25.9	14	0.534	25	15	14	14	-29.9	41.1	14	-65.5	
BP[t]+Retinoid[t]	30	15	23.3	5.2	15	23.3	16	0.416	27	16	16	15	-32.5	40.8	15	-69.9	
*Azelaic acid[t]+Macrolide[t]	37	16	23.1	9.5	16	23.1	15	0.370	19	8	15	16	-32.7	41.4	16	-70.4	
Lincosamide[t]+Retinoid[t]	32	17	21.4	7.2	17	21.4	18	0.325	18	17	18	17	-34.4	41.1	17	-73.5	
*Macrolide[t]+Anti-fungal[t]	3	18	20.0	11.5	18	19.8	22	0.316	7	18	22	18	-35.8	42.0	18	-76.3	
*Retinoid[t]+ToAc[t]+PhCh[b&	r] 39	19	17.4	13.3	20	17.1	17	0.301	21	20	17	19	-38.4	42.5	19	-81.0	
BP[t]+Macrolide[t]	29	20	17.3	9.8	19	16.8	19	0.278	16	19	19	20	-38.5	41.6	20	-81.0	
*Lincosamide[t]+ToAc[t]	36	21	15.8	11.7	23	15.4	20	0.211	29	21	20	21	-40.0	42.1	22	-83.5	
PhCh+PhTh	24	22	15.5	19.9	21	15.3	21	0.211	26	23	21	22	-40.3	38.2	21	-83.9	
Retinoid[t]	5	23	15.4	4.6	24	15.1	25	0.205	22	22	25	23	-40.4	40.7	23	-84.3	
BP[t]+Lincosamide[t]	28	24	15.1	5.5	22	13.0	27	0.198	32	24	27	24	-40.7	40.8	24	-84.9	
*Tetracycline[o]+Comb. PhPe[p	h] 8	25	13.6	14.1	26	12.9	26	0.127	38	25	26	25	-42.2	42.9	25	-88.1	
Retinoid[t]+Macrolide[t]	35	26	13.4	10.4	28	12.8	29	0.108	14	27	29	26	-42.4	41.8	26	-88.2	
Comb. chemical peels[ph]	14	27	13.3	14.1	25	12.4	32	0.089	28	26	32	27	-42.5	42.9	27	-88.8	
Benzoyl peroxide[t]	3	28	12.8	5.4	27	11.9	40	0.059	37	28	40	28	-43.0	40.7	28	-89.1	
Antiseptics[t]	8	29	10.6	11.8	29	9.5	38	0.045	23	29	38	29	-45.2	42.1	29	-93.4	

Topical acid[t]	12	30	9.3	8.5	30	8.8	36	0.037	35	32	36	30	-46.5	41.6	30	-95.8	
Macrolide[t]	7	31	8.9	5.7	31	8.7	30	0.035	31	30	30	31	-46.9	40.8	31	-96.4	
Retinoid tcd<120mg/kg(sc)[o]	16	32	8.7	12.2	32	7.0	24	0.034	39	31	24	32	-47.0	41.8	32	-96.9	
Co-cyprindiol[o]	19	33	7.6	8.1	34	7.0	23	0.018	30	33	23	33	-48.2	41.3	33	-99.0	
Comb. Oral Contraceptive[o]	20	34	7.3	5.7	33	6.8	33	0.016	36	36	33	34	-48.5	41.0	34	-99.5	
Azelaic acid[t]	6	35	6.8	6.3	35	6.4	28	0.012	33	34	28	35	-49.0	40.8	35	-100.3	
Tetracycline[o]	17	36	6.6	10.4	36	4.9	31	0.003	34	35	31	36	-49.2	41.8	36	-101.0	
Lincosamide[t]	4	37	3.4	4.6	37	2.8	35	0.002	24	38	35	37	-52.3	40.7	37	-106.7	
Macrolide[o]	18	38	0.7	14.4	38	-4.7	34	0.001	20	37	34	38	-55.1	43.0	38	-112.3	
Fusidic acid[t]	9	39	-2.5	8.8	39	-7.4	39	0.001	15	40	39	39	-58.3	41.5	39	-118.2	
*Anti-fungal[t]	11	40	-10.0	22.3	40	-24.7	37	0.000	17	39	37	40	-65.8	46.0	40	-133.3	

Abbreviations: BP Benzoyl peroxide; tcd total cumulative dose; [t] topical; [o] oral; [ph] physical; (sc) single course; ToAc Topical Acid; PhCh Photochemical therapy; PhTh Photothermal therapy; PhDy Photodynamic therapy; Comb. Combined; Rk rank (values are ranks on EV)

Mild-to-Moderate Acne

Type of model: Random study effects, fixed class effect model with 72 treatments in 40 classes relative to placebo, and bias adjustment for small study effects.

Outcome: % Change from Baseline.

MCID: 25%, GRADE probability cutoff: 0.975

Decision rules Stage 1:

EV: 38 treatment classes have positive EV LaEV: 37 treatment classes have positive LaEV

GRADE: only 1 treatment is promoted to Category 1, ranked 2nd on EV.

Ranking Systems: Pr(V>T) and Pr(Best) are erratic, respectively privileging less uncertain and more uncertain treatments. However, both Pr(Best) and SUCRA pick out the same top 3 treatments as EV; Pr(V>T) 2 of the 3.

Decision rules Stage 2:


EV: Only 2 further treatments besides the best treatment are recommended, because they are not worse than the best treatment by more than the MCID.

LaEV: Only one further treatment is recommended

GRADE: Only the single treatment in Category 1 is recommended

Comments: A number of treatments (marked with an asterisk in Table S2) were excluded from consideration by the guideline development committee on the grounds of small sample size. Two of them would have been recommended by EV. One was excluded by LaEV at Stage 2.

Fig S2 Mild to Moderate Acne



A3. Moderate to Severe Depression

Table S3.

Treatment			ST <i>A</i> Decisio	GE 1 on Rul	es									STAGE 2		
(numbering as in NICE guidelines)		EV		La	aEV		RADE (0.85) tegory 1	Rank	ing sys	tems		EV		La	aEV	GRADE (0.85) Category
	Rk	EV	Sd	Rk	LaEV	Rk	Pr(V>T)	P(Best)	SUCRA	Pr(V>T)	Rk	EV	sd	Rk	LaEV	1
Exercise group + AD 17	1	1.37	0.70	1	1.36	3	0.964	1	1	3	1(R)	0.50	0 (R)	1(R)	0.50	3
CT & CBT group + AD 25	2	1.23	0.83	2	1.20	9	0.959	2	3	9	2	0.36	1.08	3	0.14	9
CT & CBT individual + AD 6	3	1.18	0.41	3	1.18	1	0.903	4	2	1	3	0.32	0.81	2	0.10	1
Yoga group 10	4	1.05	0.61	4	1.04	10	0.883	3	4	10	4	0.19	0.92	4	-0.09	10
Self-help 21	5	0.98	0.69	5	0.95	6	0.857	5	5	6	5	0.11	0.98	5	-0.20	6
BT individual 8	6	0.86	0.38	6	0.86	7	0.856	19	6	7	6	0.00	0.79	6	-0.31	7
Light therapy + AD 11	7	0.86	0.37	7	0.86	5	0.847	26	7	5	7	-0.01	0.78	7	-0.32	
Problem solving individual 15	8	0.86	0.44	8	0.85	2	0.842	12	8	2	8	-0.01	0.82	8	-0.34	
Acupuncture + AD 39	9	0.78	0.18	9	0.78	8	0.832	8	9	8	9	-0.08	0.72	9	-0.40	
CT & CBT individual 13	10	0.78	0.27	10	0.78	4	0.832	6	10	4	10	-0.09	0.75	10	-0.43	
Counselling individual 14	11	0.67	0.41	11	0.66	11	0.699	7	11	11	11	-0.20	0.81	11	-0.62	
IPT individual+ AD 22	12	0.66	0.65	12	0.61	13	0.634	13	12	13	12	-0.21	0.95	12	-0.69	
Self-help with support 19	13	0.60	0.58	14	0.57	12	0.598	24	13	12	13	-0.26	0.91	13	-0.75	
ST PDT individual 18	14	0.58	0.36	13	0.56	14	0.584	11	14	14	14	-0.29	0.78	14	-0.76	
IPT individual 16	15	0.45	0.46	15	0.41	15	0.450	23	15	15	15	-0.42	0.83	15	-1.00	
Acupuncture 24	16	0.40	0.31	16	0.39	19	0.415	15	19	19	16	-0.46	0.76	16	-1.05	
Mirtazapine 23	17	0.35	0.07	17	0.35	16	0.338	10	16	16	17	-0.51	0.70	17	-1.12	
SNRIs 4	18	0.32	0.05	18	0.32	26	0.266	14	17	26	18	-0.54	0.70	18	-1.17	
TCAs 3	19	0.30	0.99	20	0.29	21	0.232	21	18	21	19	-0.56	1.21	20	-1.24	
ST PDP individual+AD 2	20	0.29	0.12	22	0.24	23	0.195	9	21	23	20	-0.58	0.70	22	-1.32	
CT & CBT group 12	21	0.25	0.42	21	0.19	24	0.147	16	20	24	21	-0.61	0.81	21	-1.33	
SSRIs 26	22	0.24	0.04	25	0.12	20	0.024	20	23	20	22	-0.63	0.69	19	-1.37	
Exercise group 20	23	0.20	0.56	23	0.10	17	0.015	17	26	17	23	-0.67	0.89	23	-1.45	
Exercise individual 1	24	0.14	0.61	19	0.05	18	0.003	25	24	18	24	-0.73	0.92	25	-1.53	
Trazodone 9	25	0.13	0.08	24	0.01	22	0.000	22	22	22	25	-0.74	0.70	24	-1.57	
Individual Counselling+AD 7	26	-0.29	1.32	26	-0.96	25	0.000	18	25	25	26	-1.15	1.49	26	-2.49	

Abbreviations: R=reference treatment. Rk EV Treatment ranking; AD anti-depressants; CT Cognitive therapy; CBT Cognitive Behavioural therapy; ST Short term; SSRI Selective serotonin reuptake inhibitors; SNRI Serotonin and norepinephrine reuptake inhibitors; TCA Tricyclic antidepressant; IPT Interpersonal Psychotherapy; BT Behavioural therapy; PDT Psychodynamic psychotherapy

Moderate to severe depression²

Type of model: Random study and random class effects model with 99 treatments in 50 treatment classes, relative to placebo, bias-adjusted for small study effects. The committee excluded treatments from the decision set to which less than 50 patients had been randomized, and other treatments not available in the UK. The decision set consisted of 26 classes of treatment relative to Pill Placebo

Outcome: Standardized Mean Difference

MCID: 0.50 GRADE probability cutoff: 0.85

Decision rules Stage 1:

EV: 26 treatment classes had a positive EV

LaEV: The same 26 treatment classes have positive LaEV

GRADE: No treatments were better than Pill Placebo by 0.50 with probability 0.975 or above. The probability threshold 0.85 was selected, and on this basis only 6 treatments were promoted to Category 1, included those ranked 9th and 10th on EV.

Ranking Systems: Pr(V>T) ranks treatments 3,9,10 especially highly as these have exceptionally low SD. SUCRA ranking was close to EV; Pr(Best) was highly erratic. However both Pr(Best) and SUCRA pick out the same 5 top-ranked treatments as EV.


Decision rules Stage 2:

EV: Besides the best treatment, a further four treatments are recommended, because they are not worse than the best treatment by more than the MCID.

LaEV: The same four additional treatments are recommended.

GRADE: None of the Category 1 treatments is superior to another by the MCID with probably 0.85, so none are promoted to Category 2 and all 6 are recommended

Figure S3 Moderate to severe depression



A4. Tranexamic Acid (TXA) for primary joint replacement.3

Table S4. Outcome is reduced risk of transfusion, %, relative to Intra-articular administration

Treatment			ST <i>A</i> Decisi	AGE 1 on Rul	es				_					STAGE 2		
(numbering as in NICE guidelines)		EV		La	aEV		GRADE (0.975) tegory 1	Rank	ing sys	tems		EV		LaEV GRA (0.9 Cate		
	Rk	EV	Sd	Rk	LaEV	Rk	Pr(V>T)	P(Best)	SUCRA	Pr(V>T)	Rk	EV	sd	Rk	1	
Intraarticular and oral (5)	1	6.48	4.49	1	6.33	2	0.987	1	1	2	1(R)	2.16	0 (R)	1(R)	2.16	2
Intraarticular &Intravenous (4)	2	5.50	2.99	2	5.50	1	0.933	2	2	1	2	1.19	3.26	2	0.74	
Oral (3)	3	1.11	1.87	3	0.84	3	0.169	3	3	3	3	-3.21	4.48	3	-6.81	
Intravenous (2)	4	0.55	0.99	4	0.40	4	0.003	4	4	4	4	-3.77	4.40	4	-7.84	

Tranexamic Acid (TXA) for primary joint replacement.

Type of model: Fixed study, fixed class model with 4 classes of tranexamic acid (TXA) administration relative to Intra-articular administration

Outcome: Reduction in risk of transfusion, expressed as %.


MCID: RR=1.50. GRADE probability cutoff: 0.975

Decision rules Stages 1 and 2:

EV and LaEV: all 4 treatments are superior to the reference treatment EV at Stage 1, and at Stage 2 only one is within an MCID of the best treatment GRADE: Only one treatment, ranked 2nd on EV, was promoted to Category 1, and was therefore recommended.

Ranking Systems: All three methods produced the same ranking as EV.

Figure S4. Tranexamic Acid in Joint Replacement.



A5. Headache Prophylaxis.

Table S5. Headache prophylaxis. Outcome is reduction in headache-days per month relative to placebo .

Treatment			ST <i>A</i> Decisio	AGE 1 on Rul	es									STAGE 2		
(numbering as in NICE guidelines)		EV		La	aEV	(iRADE 0.975) tegory 1	Rank	ing sys	tems		EV		La	aEV	GRADE (0.975) Category
	Rk	EV	Sd	Rk	LaEV	Rk	Pr(V>T)	P(Best)	SUCRA	Pr(V>T)	Rk	EV	sd	Rk	LaEV	1
Propranolol (6)	1	1.19	0.50	1	1.18	3	0.988	1	1	3	1(R)	0.50	0 (R)	1(R)	0.50	3
Amitriptyline (2)	2	1.14	0.66	2	1.13	1	0.925	2	2	1	2	0.45	0.78	2	0.32	
Topiramate (5)	3	1.04	0.24	3	1.04	2	0.847	3	3	2	3	0.35	0.48	3	0.29	
Propranolol & Nadolol (7)	4	0.60	0.52	4	0.57	4	0.591	4	4	4	4	-0.09	0.72	4	-0.41	
Telmisartan (1)	5	0.51	0.92	5	0.35	5	0.504	5	5	5	5	-0.18	1.04	5	-0.68	
Gabapentin (4)	6	0.00	0.81	6	-0.32	6	0.264	6	6	6	6	-0.68	0.95	6	-1.50	
Divalproex Sodium (3)	7	-0.12	0.56	7	-0.40	7	0.129	7	7	7	7	-0.81	0.75	7	-1.67	

Headache prophylaxis.

Type of model: Random effects model of 7 treatments relative to placebo

Outcome: Reduction in hospital-days per month MCID: 0.5 days. GRADE probability cutoff: 0.975


Decision rules Stages 1 & 2

EV and LaEV: At Stage 1, 6 treatments are superior to the placebo on EV and 5 on LaEV. At Stage 2, two treatments were recommended alongside the best treatment; and decisions based on EV and LaEV were identical.

GRADE: Only one treatment, the one ranked 3nd on EV, was promoted to Category 1, and was therefore recommended.

Ranking Systems: The three highest-ranked treatments on EV were also ranked highest by SUCRA, Pr(Best) and Pr(V>T).

Figure S5. Headache prophylaxis



A6: Social Anxiety (Treatment) ⁴

Table S6. Nice Guideline Social Anxiety. Outcome is improvement in clinical score, on SMD scale, relative to waitlist.

				STAC cisior	GE 1 n Rules									STAGE 2		
Treatment (numbering as in NICE guideline	s)	EV	_	L	.aEV	(GRADE (0.975) Itegory 1	Rank	king sys	tems		EV		La	aEV	GRADE (0.975) Category
	Rk	EV	Sd	Rk	LaEV	Rk	Pr(V>T)	P(Best)	SUCRA	Pr(V>T)	Rk	EV	sd	Rk	LaEV	1
CBT group Heim + Phenelzine 40	1	1.68	0.21	1	1.68	19	1.000	1	1	19	1(R)	0.50	0 (R)	1(R)	0.50	19
Cognitive therapy 35	2	1.56	0.15	2	1.56	5	1.000	2	2	5	2	0.38	0.24	2	0.37	5
Paroxetine + Clonazapam 38	3	1.35	0.29	3	1.35	7	1.000	3	5	7	3	0.17	0.31	3	0.11	7
Psychodynamic + Clonazepam 37	4	1.28	0.27	4	1.28	2	1.000	4	3	2	4	0.10	0.30	5	0.05	2
Phenelzine 22	5	1.27	0.15	5	1.27	1	1.000	6	4	1	5	0.09	0.20	4	0.02	1
CBT individual + Moclobemide 39	6	1.23	0.25	6	1.23	11	1.000	28	7	11	6	0.05	0.29	6	-0.04	11
CBT individual 34	7	1.19	0.15	7	1.19	22	1.000	8	6	22	7	0.00	0.24	7	-0.09	22
CBT group enhanced exposure 31	8	1.10	0.20	8	1.10	12	1.000	30	8	12	8	-0.08	0.27	8	-0.24	12
Clonazapam 20	9	1.07	0.19	9	1.07	13	0.999	5	9	13	9	-0.11	0.25	9	-0.28	13
CBT individual Heimberg 33	10	1.02	0.20	10	1.02	8	0.999	10	11	8	10	-0.16	0.29	10	-0.37	8
Paroxetine 17	11	0.99	0.14	11	0.99	9	0.999	18	10	9	11	-0.19	0.21	11	-0.40	9
CT abbreviated experiments 32	12	0.97	0.12	12	0.97	3	0.998	7	12	3	12	-0.21	0.23	12	-0.45	3
Venlafaxine <75 18	13	0.96	0.15	13	0.96	6	0.998	17	13	6	13	-0.22	0.21	13	-0.46	6
CBT group + Fluoxetine 36	14	0.95	0.19	14	0.95	4	0.997	23	14	4	14	-0.23	0.26	14	-0.49	4
Fluvoxamine 16	15	0.94	0.16	15	0.94	25	0.997	9	15	25	15	-0.25	0.22	15	-0.51	25
Sertraline 12	16	0.91	0.16	16	0.91	15	0.997	39	16	15	16	-0.27	0.22	16	-0.55	15
Gabapentin 10	17	0.89	0.27	17	0.89	27	0.996	14	17	27	17	-0.30	0.31	17	-0.62	27
Social skills training 24	18	0.88	0.25	18	0.88	29	0.996	26	19	29	18	-0.31	0.32	19	-0.62	29
Self-help internet with support 7	19	0.88	0.08	19	0.88	16	0.996	24	18	16	19	-0.31	0.22	20	-0.62	16
Escitalopram 14	20	0.88	0.16	20	0.88	10	0.994	12	20	10	20	-0.31	0.23	18	-0.64	10
Fluoxetine 15	21	0.87	0.15	21	0.87	21	0.992	36	21	21	21	-0.32	0.23	21	-0.64	21
CBT group 29	22	0.85	0.09	22	0.85	14	0.990	34	23	14	22	-0.33	0.21	22	-0.67	14
Alprazolam 19	23	0.85	0.28	24	0.85	20	0.990	25	24	20	23	-0.33	0.26	24	-0.68	20
Self-help book with support 6	24	0.85	0.16	23	0.85	24	0.983	33	22	24	24	-0.33	0.32	23	-0.69	24
Self-help book no support 4	25	0.84	0.12	25	0.84	31	0.943	19	25	31	25	-0.34	0.24	25	-0.69	
Citalopram 13	26	0.83	0.23	26	0.83	18	0.933	32	28	18	26	-0.35	0.28	26	-0.71	
Exposure in vivo 23	27	0.83	0.12	27	0.83	26	0.930	16	26	26	27	-0.36	0.23	27	-0.72	
Levetiracetam 9	28	0.83	0.33	28	0.83	17	0.929	20	27	17	28	-0.36	0.37	28	-0.75	
CBT group Heimberg 30	29	0.80	0.11	29	0.80	23	0.895	21	30	23	29	-0.38	0.20	29	-0.77	
Mirtazapine 11	30	0.80	0.33	30	0.80	32	0.891	15	29	32	30	-0.38	0.36	30	-0.79	

Moclobemide 21	31	0.73	0.15	31	0.73	33	0.879	11	31	33	31	-0.45	0.22	31	-0.90	
Pregabalin 400 8	32	0.72	0.18	32	0.72	28	0.839	13	32	28	32	-0.46	0.24	32	-0.93	
Self-help internet no support 5	33	0.66	0.14	33	0.66	34	0.824	31	33	34	33	-0.52	0.25	33	-1.04	
Attention-matched control 2	34	0.63	0.14	34	0.63	30	0.820	27	35	30	34	-0.55	0.23	34	-1.11	
Psychodynamic psychotherapy 28	35	0.62	0.16	35	0.62	35	0.778	40	34	35	35	-0.56	0.25	35	-1.13	
Pill Placebo 1	36	0.47	0.12	36	0.47	36	0.392	38	39	36	36	-0.72	0.20	36	-1.43	
Interpersonal psychotherapy 27	37	0.43	0.20	37	0.43	37	0.366	37	37	37	37	-0.75	0.28	37	-1.50	
Mindfulness cognitive therapy 26	38	0.39	0.22	38	0.39	39	0.338	35	36	39	38	-0.79	0.28	38	-1.58	
Exercise 3	39	0.35	0.37	39	0.31	38	0.309	22	38	38	39	-0.83	0.41	39	-1.67	
Supportive therapy 25	40	0.26	0.24	40	0.24	40	0.152	29	40	40	40	-0.92	0.30	40	-1.85	

Social Anxiety (Treatment)

Type of model: Random study effects, random class model (17 classes), with 40 individual treatments relative to waitlist control forming the decision set.^{4,5}

Outcome: Standardized Mean Difference

MCID: 0.50 GRADE probability cutoff: 0.975

Decision rules Stage 1:

EV and LaEV. All 40 treatments were superior to waitlist control.

GRADE: 24 treatments were promoted to Category 1.

Ranking Systems: SUCRA picks out the same top 7 treatments as EV. Pr(V>T) accords the highest rank to the treatment ranked 19th by EV and LaEV, due to its exceptionally low SD. Pr(Best) places the treatments ranked 28th by EV and LaEV in the top 7 treatments, due to their exceptionally high SD.


Decision rules Stage 2

EV: Besides the best treatment, a further 6 treatments are recommended, because they are not worse than the best treatment by more than the MCID.

LaEV: Only four of the six additional treatments are recommended by LaEV

GRADE: None of the Category 1 treatments is superior to another by the MCID with probability 0.975, so none are promoted to Category 2 and all 24 are recommended

Figure S6. Social Anxiety (Treatment).



A7. Social Anxiety, Class analysis⁶

Table S7. Social Anxiety, class analysis. . Outcome is improvement in clinical score, on SMD scale, relative to waitlist.

				STAC	E 1 Rules									STAGE 2 Decision Rules		
Treatment (numbering as in NICE guidelines)		EV		L	aEV	(GRADE (0.975) tegory 1	Rank	ing sys	tems		EV		Li	aEV	GRADE (0.975) Category
	Rk	EV	Sd	Rk	LaEV	Rk	Pr(V>T)	P(Best)	SUCRA	Pr(V>T)	Rk	EV	sd	Rk	LaEV	1
Combined 17	1	1.30	0.22	1	1.30	1	1.000	1	1	1	1(R)	0.50	0 (R)	1(R)	0.50	1
CBT individual 16	2	1.19	0.19	2	1.19	2	0.999	2	2	2	2	0.38	0.27	2	0.37	2
MAOI 11	3	1.00	0.28	3	1.00	6	0.995	3	3	6	3	0.20	0.33	3	0.15	6
Benzodiazepines 10	4	0.96	0.31	4	0.96	5	0.977	10	4	5	4	0.16	0.34	4	0.09	5
CBT group 15	5	0.92	0.21	5	0.92	3	0.963	4	5	3	5	0.12	0.28	6	0.06	
SSRI/SNRI 9	6	0.91	0.16	6	0.91	4	0.935	8	6	4	6	0.11	0.23	5	0.05	
Self-help with support 6	7	0.86	0.25	7	0.86	7	0.930	7	7	7	7	0.06	0.33	7	-0.04	
Exposure 12	8	0.85	0.28	8	0.85	8	0.899	5	8	8	8	0.05	0.35	8	-0.06	
Anticonvulsants 7	9	0.81	0.27	9	0.81	9	0.877	13	9	9	9	0.01	0.32	9	-0.11	
NSSA 8	10	0.80	0.42	10	0.79	11	0.851	9	10	11	10	0.00	0.45	10	-0.18	
Self-help no support 5	11	0.75	0.25	11	0.75	12	0.824	16	11	12	11	-0.05	0.33	11	-0.21	
Psychological placebo 3	12	0.63	0.14	12	0.63	10	0.765	11	13	10	12	-0.17	0.23	12	-0.38	
Psychodynamic psychotherapy 14	13	0.62	0.35	13	0.61	13	0.641	14	12	13	13	-0.18	0.41	13	-0.45	
Pill placebo 2	14	0.47	0.37	14	0.45	14	0.461	6	14	14	14	-0.33	0.40	14	-0.71	
Other psychological therapies 13	15	0.36	0.25	15	0.35	16	0.376	15	16	16	15	-0.44	0.31	15	-0.89	
Exercise promotion 4	16	0.35	0.49	16	0.28	15	0.280	12	15	15	16	-0.45	0.53	16	-0.96	

Social Anxiety, Class analysis

Type of model: Random study effects, random class model: 16 treatment classes based on 40 individual treatments, with waitlist as the reference.^{4,5}

Outcome: Standardized Mean Difference

MCID: 0.50 GRADE probability cutoff: 0.975

Decision rules Stage 1:

EV and LaEV. All 16 treatment classes were superior to waitlist control.

GRADE: 4 treatments were promoted to Category 1.

Ranking Systems: Both Pr(Best) and SUCRA pick out the same 9 top-ranked treatments as EV, and Pr(V>T) identifies 2 of them.


Decision rules Stage 2:

EV: Besides the best treatment, a further 8 treatment classes are recommended, because they are not worse than the best treatment by more than the MCID.

LaEV: Only 5 of the 8 additional treatments are recommended by LaEV.

GRADE: None of the four Category 1 treatments is superior to another by the MCID with probably 0.975, so none are promoted to Category 2 . All 4 are recommended.

Figure S7. Social Anxiety (Class Analysis)



A8. Urinary Incontinence

Table S8. Urinary incontinence. The outcome is probability of achieving continence status, relative to placebo.

Treatment				STAGE 1 cision Rules	5								STAG Decision		3	
(numbering as in NICE guidelines)		EV		LaE	V		GRADE (0.975) Itegory 1	Rank	ing sys	tems		EV		ι	aEV	GRADE (0.975) Category
	Rk	EV	Sd	Rk	LaEV	Rk	Pr(V>T)	P(Best)	SUCRA	Pr(V>T)	Rk	EV	sd	Rk	LaEV	1
Oxybutynin IR (1)	1	0.124	0.038	1	0.124	7	1.000	1	1	7	1(R)	0.043	0 (R)	1(R)	0.043	7
Tolterodine IR (4)	2	0.116	0.053	2	0.116	11	1.000	2	2	11	2	0.035	0.051	2	0.028	11
Darifenacin (11)	3	0.098	0.052	3	0.098	8	1.000	4	3	8	3	0.017	0.071	3	-0.003	8
Propiverine IR (5)	4	0.094	0.070	4	0.094	13	0.996	3	4	13	4	0.012	0.084	4	-0.014	13
Trospium (9)	5	0.084	0.047	5	0.084	6	0.993	9	5	6	5	0.002	0.067	5	-0.023	6
Oxybutynin ER (3)	6	0.079	0.038	6	0.079	3	0.989	5	6	3	6	-0.002	0.060	6	-0.027	3
Solifenacin (2)	7	0.071	0.025	7	0.071	1	0.985	6	7	1	7	-0.011	0.053	7	-0.038	1
Trospium ER (12)	8	0.070	0.028	8	0.070	10	0.982	10	8	10	8	-0.011	0.054	8	-0.039	10
Oxybutynin TG (13)	9	0.068	0.062	9	0.067	2	0.973	8	9	2	9	-0.013	0.077	9	-0.050	
Oxybutynin TD (10)	10	0.064	0.031	10	0.064	5	0.970	12	10	5	10	-0.018	0.055	10	-0.051	
Fesoterodine (8)	11	0.057	0.020	11	0.057	12	0.953	7	11	12	11	-0.025	0.049	11	-0.060	
Propiverine ER (7)	12	0.055	0.029	12	0.055	4	0.901	11	12	4	12	-0.027	0.053	12	-0.064	
Tolterodine ER (6)	13	0.036	0.014	13	0.036	9	0.793	13	13	9	13	-0.045	0.045	13	-0.095	

Urinary Incontinence

Type of model: Fixed study effects, 13 treatments compared to placebo. 7,8

Outcome: Probability of improvement in continence status

MCID: RR=1.25 *GRADE probability cutoff*: 0.975

Decision rules Stage 1:

EV and LaEV. All 13 treatments were superior to placebo.

GRADE: 8 treatments were promoted to Category 1.

Ranking Systems: SUCRA top-ranked the same 5 treatments as EV, Pr(best) 4 of them. Pr(V>T) selected none of them, but privileged treatments 11 and 13 which had exceptionally certain effects.

Decision rules Stage 2


EV: Besides the best treatment, a further 4 treatments were recommended, because they are not worse than the best treatment by more than the MCID.

LaEV: Only 1 further treatment recommended besides the best treatment.

GRADE: None of the Category 1 treatments is superior to any other by the MCID with probably 0.975, so none are promoted to Category 2, and all 8 are recommended.

Comments: The results with LaEV concur with a threshold analysis in which a plausible degree of bias (0.1 on the log odds scale) in the evidence for oxybutynin IR would make tolterodine IR the best treatment. A further point of interest in this NMA is that the guideline developers made oxybutynin IR the reference treatment, rather than placebo, from the outset. This was because it had been shown to be the best treatment in an earlier evaluation. This suggests that the 2-stage methodology, in which treatments are compared to the best treatment in the second stage, might be readily adopted by clinical decision makers.

Figure S8 Urinary Incontinence



A9. Tocolytic therapy in Preterm Labour.89

Table S9. Tocolytic therapy in preterm Labour. Outcome is increase in EGA (weeks)

Treatment			ST <i>A</i> Decisio	AGE 1 on Rul	es									STAGE 2		
(numbering as in NICE guidelines)		EV		Lá	aEV	(iRADE 0.975) tegory 1	Rank	ing sys	tems		EV		La	aEV	GRADE (0.975) Category
	Rk EV Sd		Rk	LaEV	Rk	Pr(V>T)	P(Best)	SUCRA	Pr(V>T)	Rk	EV	sd	Rk	LaEV	1	
Prostaglandin inhibs. (2)	1	2.32	0.53	1	2.32	1	0.992	1	1	1	1(R)	1.00	0 (R)	1(R)	1.00	1
Ca channel blockers (5)	2	1.68	0.50	2	1.68	2	0.915	3	2	2	2	0.37	0.53	2	0.29	
Nitrates (6)	3	1.65	0.57	3	1.65	3	0.875	2	3	3	3	0.34	0.67	3	0.21	
Magnesium sulphate (3)	4	1.28	0.50	4	1.28	5	0.723	6	4	5	4	-0.03	0.50	4	-0.25	
Betamimetics (4)	5	1.24	0.42	5	1.24	4	0.716	4	5	4	5	-0.07	0.52	5	-0.31	
Oxytocin RBs (7)	6	0.67	1.02	6	0.52	6	0.371	5	6	6	6	-0.64	1.09	6	-1.47	

Abbreviations: inhibs. Inhibitors; Ca Calcium; RBs receptor inhibitors

Tocolytic therapy in preterm Labour

Type of model: Random study effects, fixed class NMA of 6 treatment classes compared to placebo.

Outcome: Increase in Expected Gestational Age (EGA) at delivery, measured in weeks.

MCID: 1 week GRADE probability cutoff: 0.975


Decision rules Stage 1 & 2:

EV and LaEV. All 6 treatments were superior to placebo, and 2 treatments had EGA within 1 week of the best treatment. Recommendations for EV and LaEV were the same

GRADE: A single treatment is promoted to Category 1, and is therefore recommended, the same treatment was top-ranked by EV.

Ranking systems: The three treatments top-ranked on EV and LaEV are also top-ranked by all three methods

Figure S9. Tocolytic therapy in preterm Labour



APPENDIX B: WinBUGS CODE for ILLUSTRATIVE EXAMPLES

ILLUSTRATION 1:

list(nm=5, nsd=5, sdlist=c(1,2,3,4,5))

```
model {
for (s in 1:100) \{ p[s] <- pow(s/20,-2) \}
                        v[s] \sim dnorm(1,p[s])
                       el[s] <- max(0,-v[s])
                       laev[s] <- 1-el[s]
                       ev[s] <- 1.0
                        pr[1,s] \leftarrow step(v[s]-0)
                        pr[2,s] <- step(v[s]-0.5)
                        pr[3,s] <- step(v[s]-1.0)
                        pr[4,s] <- step(v[s]-1.5)
                        pr[5,s] <- step(v[s]-2.0)
                       pr[6,s] <- step(v[s]-3.0) }
}
ILLUSTRATION 2:
model {
for (s in 1:3) \{ p[s] <- pow(sd[s],-2) \}
                   v[s] \sim dnorm(m[s],p[s])
                   el[s] <- max(0,-v[s])
                   laev[s] <- v[s]-el[s] }
         }
list(m=c(1,2,3), sd=c(0.1,1,1.5))
ILLUSTRATION 4:
model {
for (i in 1:nm) { for (j in 1:nsd) {
                                                           # generates EVs at 1.1, 1.2, 1.3, 1.4, 1.5
                      m[i,j] <- 1+i/10
                      sd[i,j] <- sdlist[j]
                     pr[i,j] <- pow(sd[i,j],-2)
t[i,j] ~ dnorm(m[i,j],pr[i,j])
ev[i,j] <- t[i,j]
                                                            # incremental benefit relative to standard
                     el[i,j] \leftarrow max(0,-ev[i,j])
                                                            # exp incr value if perfect info
                      laev[i,j] <- ev[i,j] - el[i,j]
                                                            # loss-adjusted expected value
                      pv[1,i,j] <- step(t[i,j]-0.6)
                      pv[2,i,j] \leftarrow step(t[i,j]-1.3)
                     pv[3,i,j] <- step(t[i,j]-2.0)
tx[(i-1)*nsd + j] <- t[i,j] }}
for (i in 1:25) { rk[i] <- 26 - rank(tx[],i)
                                                                                       # mean rank (check)
                   pb[i] <- equals(rk[i],1)
                                                                                       # probability best
                   for (j in 1:25) { pbij[i,j] <- step(tx[i]-tx[j]) - equals(i,j) }
                                                                                      # count if (i > j)
                   su[i] <- sum(pbij[i,]) / 24 }
                                                                                       # SUCRA
}
```

APPENDIX C: WINBUGS CODE FOR NMAS

Additional code for Social anxiety Class analysis, 16 treatments

```
0.5 SMD as the MCID
# STAGE 1
for (i in 1:16) \{v[i] < --m[i+1]\}
                                                       # EV
                 la[i] <- v[i] - max(0,-v[i])
                                                       # LaEV
                 pv[i] <- step(v[i] - 0.5)
                                                       # Pr(V>T)
                 rnk[i] <- 17-rank(v[],i)
                                                       # SUCRA
                 bst[i] <- equals(rnk[i],1)}</pre>
                                                       # Pr(Best)
# STAGE 2 (treatment 16 is best)
for (i in 1:15) { v2[i] \leftarrow 0.50 - (v[16]-v[i])
                  la2[i] \leftarrow v2[i] - max(0,-v2[i]) \} # LaEV
# GRADE
for (i in 1:16) {for (j in i+1:17) { v3[j,i] < -m[j] + m[i]}
                                        gr2[j,i] \leftarrow step(v3[j,i]-0.5)}
for (j in 1:16) {for (i in j+1:17) { v3[j,i] <- -m[j] + m[i]}
                                        gr2[j,i] \leftarrow step(v3[j,i]-0.5) \}
```

Supplementary Material References

- 1. National Institute for Health and Care Excellence. Acne vulgaris: management. NICE Guideline [NG 198]. London, 2021.
- 2. National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE Guideline [NG 222]. London, 2022.
- 3. National Institute for Health and Clinical Excellence. Joint replacement (primary): hip, knee and shoulder. Network meta-analysis and cost analysis of methods for tranexamic acid administration. NG157. London, 2020.
- 4. National Institute for Health and Clinical Excellence. Social Anxiety Disorder: Recognition, Assessment and Treatment. CG159. London, 2020.
- 5. Phillippo DM, Dias S, Welton NJ, Caldwell DC, Taske N, Ades AE. Threshold Analysis as an Alternative to GRADE for Assessing Confidence in Guideline Recommendations Based on Network Meta-analyses. *Ann Intern Med* 2019; **170**: 538-46.
- 6. Mayo-Wilson E, Dias S, Mavranezouli I, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. *Lancet Psychiatry* 2014; **1**: 368-76.
- 7. National Institute for Health and Clinical Excellence. Urinary incontinence in women: the management of urinary incontinence in women. London, 2013.
- 8. Phillippo DM, Dias S, Welton NJ, Ades AE. Threshold Analysis in NICE Guideline Development, https://www.bristol.ac.uk/population-health-sciences/centres/cresyda/mpes/nice/tsu-reports/, 2016.
- 9. National Institute for Health and Clinical Excellence. Preterm labour and birth. London, 2015.